
|Videos|June 13, 2017
Dr. Fuchs Discusses Immunotherapy in Gastric Cancer
Author(s)Charles S. Fuchs, MD
Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.
Advertisement
Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.
Better therapies are needed for patients with advanced gastric cancer, says Fuchs, and immunotherapy could be an option.
PD-L1 expression is seen in gastric cancer, suggesting that immunotherapy agents—such as pembrolizumab (Keytruda)—would be effective in this commonly occurring disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































